The Medical Career And Accomplishments Of Jim Tananbaum

In an articleon INC42, Foresite Capital has announced Molly He, Ph.D. as their new venture partner. Dr. He has fifteen years of experience in her field and is extremely well respected. Jim Tananbaum, M.D. is the CEO of Foresite Capital and is thrilled she is joining their team. He believes her track record speaks for itself and she will prove to be an invaluable resource.

Dr. He worked for Illumina in scientific research and was responsible for numerous improvements regarding protein reagents. She was previously with Pacific Biosciences as the head of protein sciences. She has ten years’ experience in the pharmaceutical industry. Her focus is on drugs to help target immune diseases and cancer.

Dr. He has a Bachelor’s degree from the Nankai University in biochemistry and a Ph.D. in protein biophysics she earned while attending the University of California. She has written and published in excess of twenty papers and has issued patents and applications for patents in personalized medicine and next-generation sequencing.

Dr. He is excited about the innovative reputation of Foresite Capital. She has stated she is honored to become a part of such a dynamic team and is looking forward to the future. She believes they will make the next big breakthrough in drug discoveries and clinical research.

Jim Tananbaum is the founder and the CEO of Foresite Capital. Under his management he has acquired $1.1 billion in assets. Jim has been building and investing in healthcare companies for twenty years and his experience is substantial. Jim helped found two healthcare investment practices and two biopharmaceutical companies before Foresite was created. More  details can be found on

Jim attended Harvard Medical School and was the founder for GelTex Pharmaceuticals. The company brought the market two drugs for under eighty million. These drugs currently generate revenues of $1.6 billion. Jim additionally founded Theravance and their spin off Theravance Biopharma. Their market cap is $2.75 billion. Jim was also a partner in founding Prospect Venture Partners II and III. During an earlier time in his career he was one of the partners in Sierra Ventures and helped in the establishment of their investment practice for healthcare services. You can visit Insider Monkey for more details.

See more:

Leave a Reply

Your email address will not be published. Required fields are marked *